Clinical Study
Effect of Sulodexide on Urinary Biomarkers of Kidney Injury in Normoalbuminuric Type 2 Diabetes: A Randomized Controlled Trial
Table 3
Changes from baseline biomarkers of kidney injury.
| Parameters | Sulodexide () | Placebo () | value |
| Baseline urine TGF-beta1 (pg/mg Cr) | 14.85 ± 8.02 | 14.55 ± 10.86 | 0.920 | Change at end point (pg/mg Cr) | 2.17 ± 6.96 | 8.44 ± 9.21a | 0.020 | Baseline UACR (µg/mg Cr) | 7.44 ± 7.36 | 8.17 ± 8.21 | 0.766 | Change at end point (µg/mg Cr) | 13.89 ± 32.25 | 15.05 ± 30.09a | 0.907 | Baseline serum creatinine (mg/dL) | 1.00 ± 0.29 | 0.97 ± 0.25 | 0.728 | Change at end point (mg/dL) | −0.01 ± 0.15 | −0.06 ± 0.11 | 0.285 | Baseline estimated GFR (mL/min/1.73 m2) | 77.89 ± 34.21 | 76.17 ± 24.04 | 0.855 | Change at end point (mL/min/1.73 m2) | 4.2 ± 19.3 | 7.31 ± 14.2 | 0.565 |
|
|
Data are mean ± SD; week 14 values compared with baseline: .
|